We seek to inform and engage patients and the public with the work of The Specialist Biomedical Research Centre (BRC) for Cancer – from basic science to clinical studies – through a number of different routes.
Imaging Research open evening
The imaging research open evening welcomes patients and relatives, patient advocates, healthcare professionals, scientists and staff working in cancer support networks. The evening will provide an opportunity to meet the staff, tour the facilities and find out more about imaging research involving:
- General nuclear medicine
- SPECT/CT and PET/CT
The open evening will take place on Thursday 20 March from 5.30pm, at The Institute of Cancer Research, Sutton. For more information about the event, including how to attend, please see the flyer (PDF).
Seamless integration of research into daily clinical practice ensures that patients are actively informed of opportunities to participate in clinical research and routinely asked to consent to provide tissues for future research within The Specialist BRC for Cancer. Our current clinical trials can be found on our Clinical Trials site.
The Royal Marsden NHS Foundation Trust, in partnership with the South West London Cancer Research Network, hosts a Consumer Research Panel which is committed to patient and public involvement (PPI) in clinical research. The consumers taking part are both patients and carers representing a variety of ethnic backgrounds and age groups. The group currently meets three times annually, but utilises electronic and other forms of communication all year round. In addition, half day training sessions have continued in collaboration with South West Surrey and Hampshire (SWSH) groups. The Consumer Research Panel continues to be involved in the pre-trial review of research proposals and patient information sheets, and one member has been invited to be a member of a trial management group. The work completed on patient information sheets has resulted in changes being made to information given to patients who consider participation in research.
The Joint Annual Research Report is an ICR and Royal Marsden joint publication, which includes detailed reviews of exciting developments in selected areas of research.
The Royal Marsden’s Annual Report provides a summary of The Royal Marsden’s activities that include key achievements, governance and detailed financial information.
The ICR’s Annual Review gives an overview of the ICR’s activities, which includes research and fundraising, as well as a summary of financial information.
In Cancer Genetics, we developed a patient information booklet for BRCA mutation carriers in conjunction with Macmillan Cancer Care and patient groups. As part of the booklet, there is a patient feedback form and we will collate this data over the next year.
Patient and Carers Advisory Group (PCAG) Seminar
A one-day Research Seminar for members of The Royal Marsden’s Membership Council and Patient and Carers Advisory Group (PCAG) was held in 2009. This comprised sessions on the research process highlighting the role of The Specialist BRC for Cancer in translating the findings from the laboratory into clinical practice, and resulted in active discussion on how research is managed, funded and prioritised. The seminar provided training and information to enable the Membership Council and PCAG to be able to take a more informed, active role in research strategy, governance and management.
Agendas, minutes and documents from recent PCAG meetings are available to download.
Drug Development Unit Open Day
The Drug Development Unit conducted an open day for patients and their families, health-care professionals and others involved in patient welfare in early Phase clinical trials related to the development of new anti-cancer drugs. The meeting provided patients and their families with an opportunity to learn more about The Specialist BRC for Cancer drug development and Phase I clinical trial activity. It explored the differing perceptions of Phase I trials between clinician and patient, with an aim of identifying unmet areas of research and identifying opportunities for improving the patient experience in early Phase trials.